Category Archives: Strategy

Casing Cancer: ASCO Launches New Series on State of the Disease

Despite its importance as a vital indicator of overall population health status, cancer suffers from an information deficit – particularly when considered from a global perspective. The American Society of Clinical Oncology [ASCO], the lead professional group in this space, is now working to rectify at least part of the gap with the launch of […]
Also posted in healthcare, leadership, Market Access, pricing, R&D, Regulatory, Safety | Tagged , , , , , | Leave a comment

Europe: EFPIA Campaign Calls for Integrated Life Sciences Strategy

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign calling for an integrated life sciences  strategy for the EU. The #HealthyEU Health and Growth campaign will outline the opportunities and threats faced by patients and the healthcare sector today, and provide evidence and facts to inform healthcare debates in the run […]
Also posted in E-Media, Europe, Events, Global, multimedia, Regulatory, social media | Tagged , , , , , | Leave a comment

Changing the Hepatitis C Treatment Landscape

The American Journal of Managed Care (AJMC) recently convened an expert panel that analyzed the implications of recommendations by the US Preventive Services Task Force that all Americans born between 1946 and 1964 be screened for the hepatitis C virus (HCV). Widespread screening, along with new therapies that move patients from a chronic condition to […]
Posted in Strategy | Tagged , , | 1 Comment

Pushing the Boundaries of MS Research: The Myelin Repair Foundation

R&D’s Double Header The Myelin Repair Foundation is more than just a policy precedent – it’s also emerging as the stimulus behind a future cure for MS. The decades-old movement for “patient power” is evolving in unexpected directions, as a few vanguard organizations explicitly abandon that vague agenda around “advocacy” for something more granular and […]
Also posted in People | Tagged , , , | 1 Comment

New Fees Made FDA Worse for Generic Drug Approvals, Says GPhA Chairman

‘Actions’ don’t speak louder than words in dealing with FDA’s backlog of generic drug applications, says newly-elected GPhA Board Chairman Craig Wheeler. When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process […]
Also posted in FDA, Legal, Market Access, People, R&D, Regulatory | Tagged , , , , , , | Leave a comment
  • Categories

  • Meta